China SXT Pharmaceuticals (SXTC) Other Non-Current Liabilities (2019 - 2026)
China SXT Pharmaceuticals (SXTC) posted Other Non-Current Liabilities of $16563.0 for Q1 2026, up 2.3% on a QoQ basis from $16191.0 in Q3 2025, and down 69.26% year-over-year from $53885.0 in Q1 2025.
Powered by 
Analysis
China SXT Pharmaceuticals (SXTC) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
China SXT Pharmaceuticals has reported Other Non-Current Liabilities for 8 years, with the latest figure at $16563.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities fell 69.26% year-over-year to $16563.0 in Q1 2026; TTM through Mar 2026 was $16563.0, a 69.26% decrease from a year earlier, with the FY2026 full-year figure at $16563.0, down 69.26% from the prior year.
- Other Non-Current Liabilities was $16563.0 for Q1 2026 at China SXT Pharmaceuticals, up from $16191.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $219740.0 in Q3 2024, with the low at $16191.0 in Q3 2025.
- Average Other Non-Current Liabilities over 5 years is $112237.1, with a median of $111951.0 recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities surged 90.77% in 2024, then plunged 92.63% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $109411.0 in 2022, then soared by 33.49% to $146049.0 in 2023, then jumped by 50.46% to $219740.0 in 2024, then slumped by 92.63% to $16191.0 in 2025, then grew by 2.3% to $16563.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $16563.0 (Q1 2026), $16191.0 (Q3 2025), and $53885.0 (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn |
| 10 | China SXT Pharmaceuticals | 19,200.96 | -28.16 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 16,563.00 |
| Sep 30, 2025 | 16,191.00 |
| Mar 31, 2025 | 53,885.00 |
| Sep 30, 2024 | 219,740.00 |
| Mar 31, 2024 | 213,571.00 |
| Sep 30, 2023 | 146,049.00 |
| Mar 31, 2023 | 111,951.00 |
| Sep 30, 2022 | 109,411.00 |
| Mar 31, 2022 | 122,773.00 |
| Sep 30, 2021 | 480,227.00 |
| Mar 31, 2021 | 472,282.00 |
| Sep 30, 2020 | 104,814.00 |
| Mar 31, 2020 | 113,611.00 |
| Sep 30, 2019 | 73,533.00 |
| Mar 31, 2019 | 78,317.00 |